GlassScriptPhysician profile
Christopher Broyles Carter
NPI 1962766840
$7,550.36
in general payments reported to CMS, 2019-2025
40 companies · $1,146 in 2025
The $1,146 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,082 · 2020: $331 · 2021: $1,069 · 2022: $1,289 · 2023: $1,279 · 2024: $1,355 · 2025: $1,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,779.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $828.27 | 2019-2025 | |
| Abbvie INC. | $764.44 | 2021-2025 | Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $750.68 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $624.63 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $603.78 | 2019-2025 | Jardiance |
| Amgen INC. | $559.72 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $522.66 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $467.47 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $395.35 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $299.14 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $269.21 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $168.73 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $152.53 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $134.10 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $118.65 | 2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.